Accelerating Therapeutic DiscoveryTM

News From The Alpha-1 Project

18
SAN DIEGO, September 4, 2019 /PRNewswire/ — Inhibrx, Inc. (Inhibrx), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today the enrollment of the first patient in ...

[Read More...]

08
Arrowhead Pharmaceuticals Inc., has dosed the first patient in SEQUOIA (AROAAT2001), a potentially pivotal Phase 2/3 clinical study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD).

[Read More...]

24
Up to $162.5M in upfront, cost sharing and milestone payments, and escalating royalties into the high teens assuming exercise of the option   SAN DIEGO, May 30, 2019 /PRNewswire/ — Inhibrx, Inc. (“Inhibrx”), a clinical-stage ...

[Read More...]

03
Dicerna begin the clinical development phase of an A1AT deficiency-associated liver disease program

[Read More...]

30
Arrowhead Pharmaceuticals granted FAST TRACK status for first potential AATD liver disease therapeutic.

[Read More...]

Page 1 of 5First   Previous   [1]  2  3  4  5  Next   Last